All In Biotech

Drug Trial Radar · NCT06205706

BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors

Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First-in-Human, Consecutive-Cohort, Clinical Trial of BI-1910, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

35

Actual

Start

Dec 4, 2023

Primary completion

Jul 14, 2027

Study completion Nov 7, 2028

Sponsor

Lead sponsor
BioInvent International ABIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Jan 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this first in human clinical trial is to test BI-1910 administered as single agent and in combination with pembrolizumab in subjects with advanced/metastatic solid tumors whose disease has progressed after standard therapy. The main questions it aims to answer are: * how safe and tolerable is BI-1910 * what is maximum tolerated or administrated dose * to determine recommended dose for further clinical trials Participants will receive infusions of BI-1910 alone or combination with pembrolizumab every 3 weeks.

Conditions

  • Solid Tumors
  • Non Small Cell Lung Cancer
  • Hepatocellular Carcinoma

Interventions

  • BI-1910Drug

    BI-1910 administered as a flat-dose IV infusion once every 3 weeks

  • PembrolizumabDrug

    Pembrolizumab be administered as an IV infusion at its standard flat dose (200 mg) once every 3 weeks prior to the BI-1910 infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of adverse events (AEs)Time frame: From the start of the study treatment for up to 2 years and 90 days.
  2. Occurrence of serious adverse events (SAEs)Time frame: From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days
  3. Frequency of AEs leading to discontinuation of study treatmentTime frame: From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days
  4. Frequency of dose interruptions and dose reductions.Time frame: From the start of the study treatment for up to 2 years
  5. Changes from baseline in laboratory parametersTime frame: From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days
  6. Changes from baseline in temperature (C or F)Time frame: From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days
  7. Changes from baseline in Respiratory Rate (Breaths/Min)Time frame: From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days
  8. Changes from baseline in Blood Pressure (mmHg)Time frame: From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days
  9. Changes from baseline in O2 Saturation (%)Time frame: From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days
  10. Changes from baseline in weightTime frame: From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days
  11. Occurrence of dose limiting toxicities (DLTs)Time frame: During phase 1 Part A: from the first dose of BI-1910 for 21 days. During phase 1 part B: from the first dose of BI-1910 for 42 days.
  12. identification of dose/dose range fulfilling favorable PK and pharmacodynamic profile, with acceptable safetyTime frame: During phase 2a from screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days

Locations

8 sites in 4 countries. Site status is shown where the registry gives one.

  • Rigshospitalet

    Copenhagen, Denmark

  • Universitätsklinikum Essen

    Essen, Germany

  • Hospital HM Nou Delfos

    Barcelona, Spain

  • HM Sanchinarro

    Madrid, Spain

  • Hospital Fundacion Jimenez Diaz

    Madrid, Spain

  • Hospital universitario Virgen del Rocio

    Seville, Spain

  • Lund University Hospital

    Lund, Sweden

  • Karolinska University Hospital, Solna

    Stockholm, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.